Sera Prognostics Inc. (NASDAQ: SERA), a company focused on improving maternal and neonatal health through innovative pregnancy biomarker information, has announced two upcoming investor events where it will share updates on its business progress and financial performance.
The Salt Lake City-based diagnostics firm will participate in the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, 2025. President and CEO Zhenya Lindgardt will engage in a fireside chat from 9:50 a.m. to 10:20 a.m. ET, providing insights into the company's recent achievements and strategic direction. Investors and interested parties can access a live webcast of the presentation through Sera's investor relations website.
Additionally, the company has scheduled the release of its first quarter fiscal year 2025 financial results for Wednesday, May 7, 2025, after market close. Management will host a conference call and webcast at 5:00 p.m. ET to discuss operational highlights, financial performance, and key developments. The call will be accessible to U.S. domestic callers at (800) 836-8184 and international callers at (646) 357-8785, with a webcast available on the company's website.
Addressing the Challenge of Preterm Birth
Sera Prognostics has positioned itself as "The Pregnancy Company®" with a clear focus on addressing preterm birth, defined as any birth before 37 weeks' gestation. According to the 2024 March of Dimes Report Card cited by the company, more than one in ten infants in the United States has been born prematurely for five consecutive years.
Preterm birth represents a significant public health concern as the leading cause of illness and death in newborns. The condition is associated with substantial long-term medical complications, including learning disabilities, cerebral palsy, chronic respiratory illness, intellectual disability, seizures, and vision and hearing loss. The economic impact is equally significant, with annual healthcare costs to manage preterm birth complications in the United States estimated at approximately $25 billion as of 2016.
The PreTRM® Test: A Precision Medicine Approach
At the center of Sera's commercial strategy is the PreTRM® Test, described as the only broadly validated, commercially available blood-based biomarker test providing early, accurate, and individualized risk prediction for spontaneous preterm birth in asymptomatic singleton pregnancies.
The test works by measuring and analyzing specific proteins in the blood that have been identified as highly predictive of preterm birth. Designed to be administered during weeks 18 through 20 of pregnancy, the PreTRM® Test enables physicians to identify women at increased risk for preterm birth and its complications. This early risk assessment allows for more informed, personalized clinical decisions based on each woman's individual risk profile.
The company emphasizes that the test must be ordered by a medical professional, positioning it firmly within the clinical care pathway rather than as a direct-to-consumer product.
Growth Strategy and Market Opportunity
Sera Prognostics has indicated it maintains a robust pipeline of innovative diagnostic tests focused on the early prediction of preterm birth risk and other pregnancy complications. This suggests the company is working to expand its offerings beyond its flagship PreTRM® Test.
The company's broader mission centers on providing early, pivotal pregnancy information to improve maternal and newborn health outcomes while potentially reducing healthcare delivery costs. This value proposition aligns with growing healthcare industry emphasis on preventive care and early intervention to improve outcomes and reduce costs.
As Sera prepares for these upcoming investor events, stakeholders will be watching for updates on commercial adoption of the PreTRM® Test, progress on reimbursement initiatives, and advancements in the company's diagnostic pipeline. The presentations may also provide insights into how Sera is navigating the evolving regulatory landscape for laboratory-developed tests and its strategies for expanding market penetration in the maternal-fetal health space.
